Bespoke research fueled by a community of leading minds to accelerate your digital health strategy & get ahead of the market.Contact Advisory
By embracing digital measures, pharma can accelerate drug development, improve patient outcomes. Pharma can and will continue to compete on assets, but should not compete on (digital) endpoints. We require industry collaborations in order to usher in a new era of medicine.
Digital measures have the potential to revolutionise drug development. However, pharma has been slow to fully utilise these measures due to their high costs and lack of standardised applications across therapeutic areas.
This report presents an expert-led analysis of the state of digital measures in drug development. More specifically, the report delves into:
Download the report to learn what our HealthXL community experts believe is in store for the future of digital measures in drug development and how best to prepare for it.